Advertisement
GMED vs VIVO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMED is a Hold and VIVO is a Buy.
Momentum Indicator for GMED turns positive, indicating new upward trend
GMED saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 63 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 72%.
Technical Analysis (Indicators)
Bullish Trend Analysis
GMED moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GMED crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +1.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 202 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 62 cases where GMED's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
GMED broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GMED entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. GMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 68 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.241) is normal, around the industry mean (4.170). P/E Ratio (20.045) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
VIVO's Stochastic Oscillator descends into oversold zone
The Stochastic Oscillator for VIVO moved into oversold territory on November 03, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for VIVO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
Following a +15.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVO advanced for three days, in 186 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
VIVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VIVO as a result. In 79 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for VIVO turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 42 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 50-day moving average for VIVO moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VIVO entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. VIVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.139) is normal, around the industry mean (16.526). P/E Ratio (-0.833) is within average values for comparable stocks, (57.809). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.287) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (103.889).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
GMED | VIVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 96 | 100 | |
SMR RATING 1..100 | 65 | 100 | |
PRICE GROWTH RATING 1..100 | 48 | 85 | |
P/E GROWTH RATING 1..100 | 68 | 8 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GMED's Valuation (76) in the Medical Specialties industry is in the same range as VIVO (95) in the Biotechnology industry. This means that GMED’s stock grew similarly to VIVO’s over the last 12 months.
GMED's Profit vs Risk Rating (96) in the Medical Specialties industry is in the same range as VIVO (100) in the Biotechnology industry. This means that GMED’s stock grew similarly to VIVO’s over the last 12 months.
GMED's SMR Rating (65) in the Medical Specialties industry is somewhat better than the same rating for VIVO (100) in the Biotechnology industry. This means that GMED’s stock grew somewhat faster than VIVO’s over the last 12 months.
GMED's Price Growth Rating (48) in the Medical Specialties industry is somewhat better than the same rating for VIVO (85) in the Biotechnology industry. This means that GMED’s stock grew somewhat faster than VIVO’s over the last 12 months.
VIVO's P/E Growth Rating (8) in the Biotechnology industry is somewhat better than the same rating for GMED (68) in the Medical Specialties industry. This means that VIVO’s stock grew somewhat faster than GMED’s over the last 12 months.
| GMED | VIVO | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 65% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 72% | 2 days ago 90% |
| MACD ODDS (%) | N/A | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 58% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 61% | 2 days ago 90% |
| Advances ODDS (%) | 2 days ago 66% | 8 days ago 84% |
| Declines ODDS (%) | 17 days ago 58% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 67% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMED’s FA Score shows that 0 FA rating(s) are green while VIVO’s FA Score has 1 green FA rating(s).
- GMED’s FA Score: 0 green, 5 red.
- VIVO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMED’s TA Score shows that 4 TA indicator(s) are bullish while VIVO’s TA Score has 4 bullish TA indicator(s).
- GMED’s TA Score: 4 bullish, 4 bearish.
- VIVO’s TA Score: 4 bullish, 5 bearish.
Price Growth
GMED (@Medical/Nursing Services) experienced а -1.63% price change this week, while VIVO (@Computer Communications) price change was -39.16% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.01%. For the same industry, the average monthly price growth was -7.51%, and the average quarterly price growth was -8.84%.
The average weekly price growth across all stocks in the @Computer Communications industry was -6.19%. For the same industry, the average monthly price growth was -11.87%, and the average quarterly price growth was -6.36%.
Reported Earning Dates
GMED is expected to report earnings on Nov 05, 2026.
VIVO is expected to report earnings on Dec 02, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.01% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Computer Communications (-6.19% weekly)Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.
Advertisement
VIVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIVO has been loosely correlated with INSP. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVO jumps, then INSP could also see price increases.
| Ticker / NAME | Correlation To VIVO | 1D Price Change % | ||
|---|---|---|---|---|
| VIVO | 100% | -27.44% | ||
| INSP - VIVO | 41% Loosely correlated | -7.90% | ||
| ICLR - VIVO | 38% Loosely correlated | -0.67% | ||
| BRKR - VIVO | 37% Loosely correlated | +1.45% | ||
| GMED - VIVO | 36% Loosely correlated | +0.15% | ||
| TMO - VIVO | 35% Loosely correlated | +2.30% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ISCG | 61.53 | 0.40 | +0.65% |
| iShares Morningstar Small-Cap Growth ETF (ISCG) | |||
| ITOT | 164.70 | 0.55 | +0.34% |
| iShares Core S&P Total U.S. Stock Market ETF (ITOT) | |||
| PVEX | 30.18 | 0.01 | +0.02% |
| TrueShares ConVex Protect ETF (PVEX) | |||
| XTJA | 35.53 | N/A | N/A |
| Innovator U.S. Equity Accelerated Plus ETF - January (XTJA) | |||
| RSPS | 31.31 | -0.66 | -2.06% |
| Invesco S&P 500 Equal Weight Consumer Staples ETF (RSPS) | |||